Article
New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams
6 Dec 2020
Abstract excerpt
Carbapenem resistance is a major global health problem that seriously compromises the treatment of infections caused by nosocomial pathogens. Resistance to carbapenems mainly occurs via the production of carbapenemases, such as VIM, IMP, NDM, KPC and OXA, among others. Preclinical and clinical trials are currently underway to test a new generation of promising inhibitors, together with the recently approved...
Topics
Join the communities discussing this publication.